Undisclosed next-generation selective peptide MC4R agonist / Palatin Technologies - LARVOL DELTA

Obesity Program Update (The Malaysian Reserve) - "PL7737 (oral MC4R agonist)...IND-enabling toxicology studies are progressing as planned, with an IND submission and initiation of a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial anticipated in the first half of 2026; Next-generation selective peptide MC4R agonists: Designed for once-weekly subcutaneous dosing, with an IND submission and initiation of a Phase 1 SAD/MAD trial targeted for the second half of 2026."

IND • New P1 trial • Hypothalamic Injury-associated Obesity • Obesity